Open Accessibility Menu

Coronavirus (COVID-19) Vaccine Update Click here to learn more.

For information about COVID-19 or to view additional resources, please click here.

Dermatology

There’s so much you can do to keep your skin healthy and beautiful. Our dermatologists over a wide array of cosmetic skin treatments for patients of all skin types and ethnicities.

male patient using a light to look at patients skin on arm

Divisions and Centers

  • The GW Department of Dermatology offers comprehensive general dermatology and cutaneous oncology services.

    Learn More
  • Keep your skin looking happy and healthy with our experienced team of cosmetic dermatology providers.

    Learn More

Clinical Trials

  • Light Treatment Effectiveness (LITE) Study. The purpose of this study is to compare the effectiveness, safety (tolerability), and duration of treatment response at 12 weeks of home versus office-based NB-UVB phototherapy for the treatment of psoriasis

    Main inclusion criteria:

    1. Must be a new or established patient seen in the dermatology clinic, > 12 years old, and your provider must recommend NB-UVB (narrow band ultra violet) phototherapy (also called light therapy) for the treatment of psoriasis.
  • KPL-716-C201: A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritus in Subjects with Prurigo Nodularis

    Main inclusion criteria:

    1. Clinical diagnosis of PN for at least 6 months.
       
    2. Have at least 20 nodules of approximately 0.5 to 2 cm. The nodules must be pruritic and present on at least 2 different anatomical locations (not be localized), involve the extremities, with extensor extremity involvement greater than the flexor extremity involvement. Nodules on the head (face and scalp) are not counted as an anatomical location for eligibility criteria. Each arm, each leg, and trunk are considered different anatomical locations. IGA score of ≥3.
       
    3. Subject has moderate to severe pruritus, defined as WI-NRS ≥7.
  • A study to assess the efficacy and safety of nemolizumab (CD14152) in subjects with prurigo nodularis (PN)

    Main inclusion criteria:

    1. Clinical diagnosis of PN for at least 6 months with Pruriginous nodular lesions on upper limbs, trunk, and/or lower limbs. At least 20 nodules on the entire body with a bilateral distribution with IGA score ≥ 3.
       
    2. Severe pruritus defined as ≥ 7 on the PP NRS.
       
    3. Lack of any other primary pruritic skin condition.
  • A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy, and Safety Study in Prurigo Nodularis with Nalbuphine ER Tablets for Pruritus Relief Through Itch Scratch Modulation (PRISM Study)

    Main inclusion criteria:

    1. Individuals diagnosed with generalized PN, defined as the presence of ≥ 10 pruriginous nodules, involving at least 2 distinct anatomical areas: for example, either 2 limbs; or a single limb and some axial portion of the body.
       
    2. If there is any history of a primary pruritic skin condition other than PN, that condition must have been inactive for at least 6 months prior to screening.
  • TARGET-DERM: A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Immune-Mediated Inflammatory Skin Conditions (Atopic Dermatitis)

    Main inclusion criteria:

    1. Atopic Dermatitis with IGA ≥ 3 or use of biologics.

  • A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis.

    Main inclusion criteria:

    1. Chronic AD for at least 2 years with EASI ≥ 16 and IGA score ≥ 3. AD involvement ≥ 10% of body surface area.
       
    2. Documented recent history (within 6 months) of inadequate response to TCS.
       
    3. Documented recent history (within 6 months) of inadequate response to TCI if the patient has been using TCI.